Integra LifeSciences Aims To Shutter Two Plants, Discontinue Low-Growth Products
This article was originally published in The Gray Sheet
Executive Summary
The plans are part of a strategy to consolidate manufacturing operations while prioritizing fast-growing, high-margin regenerative medicine products.
You may also be interested in...
Extremities, Emerging Markets Continue To Top M&A Ortho Interest
With hip and knee joint markets still registering slow to modest growth, orthopedic companies looking to add bulk to their bottom line through mergers and acquisitions have pursued two distinct directions – the extremities and emerging markets.
New EU Filings
Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
UK Guidance Tackles Social Media ‘Compliance Headache’ For Pharma
Announcing product milestones and liking LinkedIn posts are just some of the topics addressed in a long-awaited guidance that deals with the challenges prescription drug makers face in the UK when using social media.